Serplulimab for locally advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- Your cancer is locally advanced (stage IB2-IIB with positive lymph nodes, or stage III-IVA) and has not spread to distant parts of your body.
- You are between 18 and 75 years old.
- You have not had any prior anti-tumor treatment for this cancer.
- Your overall health is good enough to perform daily activities (ECOG score 0 or 1).
- You are willing to use effective contraception during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This study tests a combination of two chemotherapy drugs (nab-paclitaxel and cisplatin) given alongside radiation therapy for people with locally advanced cervical cancer. The goal is to see if this combination is safe and effective in shrinking the cancer and improving outcomes.
This trial tests adding an immunotherapy drug (serplulimab) to standard chemoradiation after cervical cancer surgery. It is for patients with at least two high-risk features, like lymph node spread or deep invasion, to see if it helps prevent the cancer from coming back.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. It is for those who have not had any previous treatment for their cancer.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.